McKesson (MCK) and Oracle (ORCL) are among the finalists seeking to buy electronic medical records company Veradigm (MDRX), Claire Rychlewski of Axios reported Sunday, citing sources. A deal could top Veradigm’s $1B market cap due to the lower antitrust risk from the incoming Trump administration, according to the report. CVS Health (CVS) had looked at Veradigm but dropped out amid its own strategic review, according to sources.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCK:
- McKesson price target raised to $651 from $642 at TD Cowen
- JPMorgan, Five Below downgraded: Wall Street’s top analyst calls
- Early notable gainers among liquid option names on November 7th
- McKesson price target raised to $668 from $616 at Barclays
- McKesson upgraded to Outperform from Neutral at Baird